Alpha Teknova, Inc. Common Stock (TKNO) is a publicly traded Healthcare sector company. As of May 21, 2026, TKNO trades at $4.20 with a market cap of $194.08M and a P/E ratio of -11.33. TKNO moved -2.15% today. Year to date, TKNO is -7.50%; over the trailing twelve months it is -44.94%. Its 52-week range spans $1.91 to $10.37. Analyst consensus is buy with an average price target of $9.50. Rallies surfaces TKNO's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Teknova Q1 Revenue Rises 13% to $11.1M, Clinical Solutions Up 85%: Teknova delivered 13% revenue growth to $11.1M in Q1 2026, with Lab Essentials revenue up 3% to $8.4M and Clinical Solutions soaring 85% to $2.1M. The company reaffirmed full-year 2026 revenue guidance of $42-44M and forecasts free cash outflow below $10M, supported by $17.8M in cash.
| Metric | Value |
|---|---|
| Price | $4.20 |
| Market Cap | $194.08M |
| P/E Ratio | -11.33 |
| EPS | $-0.32 |
| Dividend Yield | 0.00% |
| 52-Week High | $10.37 |
| 52-Week Low | $1.91 |
| Volume | 3.13K |
| Avg Volume | 0 |
| Revenue (TTM) | $41.80M |
| Net Income | $-17.17M |
| Gross Margin | 34.01% |
5 analysts cover TKNO: 0 strong buy, 3 buy, 2 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $9.50.